Justice Department clears Viatris of charges in generic drug antitrust investigation

The Justice Department does not expect to take further action against Viatris on its request to initiate a civil investigation into the pricing and sale of generic drugs.

Viatris said the U.S. Department of Justice’s Antitrust Division has indicated it no longer considers Mylan or its former CEO Rajiv Malik to be the subject of an antitrust investigation into the generics industry.

The Civil Division also informed the company that it did not intend to take further action on the request to initiate a civil investigation into the pricing and sale of generic drugs.

Viatris said the finding confirms the company’s long-standing position that Mylan thoroughly investigated these allegations and found no evidence of misconduct by Mylan or its employees.

(Read more: The Mylan-Upjohn combination will be called Viatris)

The company also said it was satisfied that it had concluded the Department of Justice’s investigations and intended to continue to defend itself against any remaining civil lawsuits related to these matters.